Department of Medical Oncology and Hematology of the University Health Network, Princess Margaret Hospital Site and the University of Toronto, Toronto, Ontario, Canada.
J Thorac Oncol. 2010 May;5(5):723-34. doi: 10.1097/JTO.0b013e3181d86e8b.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the industrialized world, and survival rates for advanced disease remain low with standard platinum-based chemotherapy. One treatment strategy that has been investigated extensively in NSCLC is that of "maintenance" therapy. Options for maintenance include maintaining response to initial therapy by continuing the initial combination chemotherapy regimen, continuing only single agent chemotherapy, or by introducing a new agent. Treatments that have been studied in randomized trials to date include chemotherapy, molecularly targeted agents, and immunotherapy approaches. After the development of multiple new agents that show activity in NSCLC and have a tolerable side effect profile, there has been increasing interest recently in this treatment strategy. In this study, we examine the evolution of this strategy by reviewing trials investigating the main treatment paradigms used in maintenance therapy for NSCLC.
非小细胞肺癌（NSCLC）是工业化国家癌症死亡的主要原因，晚期疾病的生存率仍然很低，标准的铂类化疗效果不佳。在 NSCLC 中，一种已被广泛研究的治疗策略是“维持”治疗。维持治疗的选择包括通过继续初始联合化疗方案、仅继续单药化疗或引入新药物来维持对初始治疗的反应。迄今为止，在随机试验中研究过的治疗方法包括化疗、分子靶向药物和免疫治疗方法。随着多种新药物在 NSCLC 中显示出活性且副作用可耐受，最近人们对这种治疗策略的兴趣日益增加。在这项研究中，我们通过回顾 NSCLC 维持治疗中主要治疗模式的试验，研究了这一策略的演变。
Zotero 插件